1103TiP - MEDIOLA: A phase I/II, open-label trial of olaparib in combination with durvalumab (MEDI4736) in patients (pts) with advanced solid tumours

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Immunotherapy
Therapy
Presenter Susan Domchek
Citation Annals of Oncology (2016) 27 (6): 359-378. 10.1093/annonc/mdw378
Authors S. Domchek1, Y. Bang2, G. Coukos3, K. Kobayashi4, N. Baker5, E. McMurtry6, W. Song4, B. Kaufman7
  • 1Basser Research Center, Abramson Cancer Center, PA 19104 - Philadelphia/US
  • 2Biomedical Research Institute, Seoul National University College of Medicine, Seoul/KR
  • 3Ludwig Institute For Cancer Research, University Hospital of Lausanne, Lausanne/CH
  • 4Oncology, AstraZeneca, Gaithersburg/US
  • 5Statistical Science, AstraZeneca, Cambridge/GB
  • 6Oncology, AstraZeneca, Macclesfield/GB
  • 7Breast Cancer Unit, Sheba Medical Center, Tel Hashomer/IL

Abstract

Background

Olaparib (Lynparza) is a potent, oral PARP inhibitor that induces synthetic lethality in tumours deficient in homologous recombination repair. Durvalumab is a selective, high-affinity, engineered, human IgG1 mAb that blocks PD-L1 binding to PD-1 and CD80, preventing PD-L1-mediated inhibition of T-cell activation, and promoting antitumour immune responses. In a Phase I study (NCT02484404), olaparib plus durvalumab was tolerable, and a recommended combination dose was determined (Lee et al, ASCO 2016). MEDIOLA (NCT02734004) is using this combination dose to assess olaparib and durvalumab, which may have complementary mechanisms of action, in pts selected using criteria that predict sensitivity to olaparib.

Trial design

MEDIOLA has four pt cohorts: pts with platinum-sensitive recurrent ovarian cancer (OC) who have received ≥2 lines of platinum-based therapy and have a known/suspected deleterious germline BRCA1/2 mutation (gBRCAm); pts with unresectable, advanced, gBRCAm, HER2-negative breast cancer (BC) who have received anthracycline/taxane therapy; pts with small-cell lung cancer (SCLC) that has relapsed >12 weeks (wks) after platinum-based therapy; and pts with advanced ATM-negative gastric cancer (GC) that has progressed after first-line chemotherapy. Pts will receive olaparib monotherapy (300 mg bid, tablets) for 4 wks, then olaparib (300 mg bid) plus durvalumab (1500 mg IV q4w) until disease progression. Disease will be assessed by CT/MRI at baseline, after olaparib monotherapy and every 8 wks during the combination phase. Primary objectives are disease control rate (DCR) at 12 wks (includes pts with complete/partial response or stable disease) by modified RECIST 1.1 (using a post-progression scan), safety and tolerability. Secondary endpoints include pharmacokinetics, DCR at 28 wks, objective response rate, progression-free survival and overall survival. Cohorts will be considered as individual Bayesian predictive probability designs. Initially, 10 pts/cohort will be enrolled across ∼17 centres worldwide, with expansion to n = 30 (OC), n = 38 (BC), n = 34 (SCLC) and n = 37 (GC) after interim assessment. Enrolment began in Q1 2016.

Clinical trial identification

NCT02734004

Legal entity responsible for the study

AstraZeneca

Funding

AstraZeneca

Disclosure

S. Domchek: The University of Pennsylvania has received research funding from AbbVie, and Clovis. Dr. Domchek has received an honorarium from EMD Serrano. Y-J. Bang: Research funds from AstraZeneca (through institution), and consulted for AstraZeneca. G. Coukos: Commercial research grants: Celgene, Boehringer-Ingelheim. Honoraria from Speakers Bureau: Roche, Genentech. Consultant or Advisory Roles: Genentech, Roche, Novartis, Sanofi-Aventis. K. Kobayashi, N. Baker, E. McMurtry, W. Song: AstraZeneca employee and AstraZeneca stock ownership. B. Kaufman: Participation in an advisory board for AstraZeneca.